RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai’s Everest Medicines acquired global rights to a novel Novartis liver cancer treatment. FGF401, a FGFR4 (fibroblast growth factor receptor 4) kinase inhibitor, is currently in Phase I/II clinical trials across the US, Europe and Asia as a potential treatment for hepatocellular carcinoma and other solid tumors positive for FGFR4 and KLB (klotho beta) expression. Founded last year, Everest began operations with a $50 million investment from C-Bridge Capital, the first tranche of an initial round expected to raise $130 million.
Source: China Biotoday
